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Introduction: The relative roles of surgery and stereotactic body 
radiation therapy in stage I non–small-cell lung cancer (NSCLC) are 
evolving particularly for marginally operable patients. Because there 
is limited prospective comparative data for these treatment modali-
ties, we evaluated their relative use and outcomes at the population 
level using a national database.
Methods: Patient variables and treatment-related outcomes were 
abstracted for patients with clinical stage I NSCLC from the National 
Cancer Database. Patients receiving surgery were compared with 
those undergoing stereotactic body radiation therapy (SBRT) in 
exploratory unmatched and subsequent propensity matched analyses.
Results: Between 1998 and 2010, 117,618 patients underwent sur-
gery or SBRT for clinical stage I NSCLC. Of these, 111,731 (95%) 
received surgery, whereas 5887 (5%) underwent SBRT. Patients in 
the surgery group were younger, more likely to be males, and had 
higher Charlson comorbidity scores. SBRT patients were more likely 
to have T1 (versus T2) tumors and receive treatment at academic 
centers. Thirty-day surgical mortality was 2596 of 109,485 (2.4%). 
Median overall survival favored the surgery group in both unmatched 
(68.4 versus 33.3 months, p < 0.001) and matched analysis based on 
patient characteristics (62.3 versus 33.1 months, p < 0.001). Disease-
speciﬁc survival was unavailable from the data set.
Conclusion: In a propensity matched comparison, patients selected 
for surgery have improved survival compared with SBRT. In the 
absence of information on cause of death and with limited variables 
to characterize comorbidity, it is not possible to assess the relative 
contribution of patient selection or better cancer control toward the 
improved survival. Rigorous prospective studies are needed to opti-
mize patient selection for SBRT in the high-risk surgical population.
Key Words: Non–small-cell lung cancer, Surgery, Stereotactic body 
radiation therapy, Outcomes.
(J Thorac Oncol. 2015;10: 1776–1784)
Surgical resection has been traditionally considered the stan-dard procedure in patients with clinical stage I non–small-
cell lung cancer (NSCLC). Stereotactic body radiation therapy 
(SBRT) was introduced over a decade ago as an alternative to 
conventionally fractionated radiation therapy in patients con-
sidered medically inoperable. Since then, the application of 
SBRT has expanded, and it is often considered in patients who 
may be surgical candidates but face a potentially higher risk 
of perioperative morbidity or mortality. Several retrospective 
institutional studies have compared early and intermediate-
term outcomes after these two treatment modalities1–9 yet 
high-quality prospective trial data remain elusive.
Most comparative studies have generally found 
patients undergoing surgery to have longer overall survival 
(OS) when compared with SBRT patients3,7,10 particularly 
when the operation performed is a lobectomy. However, 
studies comparing local/regional recurrence and disease-
free survival (DFS) after surgery or SBRT have shown mixed 
results.1,3,8,9 A part of the problem comparing locoregional 
control is the lack of uniformity between treating specialties 
(surgeons and radiation oncologists) and individual studies 
in deﬁnitions of local and regional recurrence as well as the 
varying schedules of follow-up imaging studies employed 
after surgery or SBRT. In addition, both treatment modalities 
have evolved with the widespread use of thoracoscopic tech-
niques in surgery and the improvement of radiation doses 
and fractions in SBRT.
The literature contrasting SBRT and surgery has largely 
come from major academic centers with leading radiation 
oncology and thoracic surgery programs. Another criticism of 
the institutional studies has been the relatively short follow-
up in the SBRT cohorts. Recent claims database analyses 
have studied surgery and SBRT for lung cancer in the elderly 
population.11,12
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The National Cancer Data Base (NCDB), a joint pro-
gram of the Commission on Cancer of the American College 
of Surgeons and the American Cancer Society, is a nationwide 
oncology outcomes database for more than 1500 commission-
accredited cancer programs. About 70% of all newly diag-
nosed cases of cancer in the United States are captured at the 
institutional level and reported to the NCDB.13,14 We aimed 
to study the actual practice patterns of treatment for stage I 
NSCLC in the United States and understand the relative efﬁ-
cacy of surgical resection and SBRT in this population using 
the NCDB.
PATIENTS AND METHODS
Using deidentiﬁed patient information from the NCDB 
participant user ﬁle, we abstracted information on patients with 
clinical stage I NSCLC who received treatment between 1998 
and 2010 with either surgical resection (surgery) or SBRT. 
Patients who did not receive either one of these two treatment 
plans (surgery or SBRT) were excluded. Speciﬁcally, the sur-
gical cohort began in 1998, whereas the ﬁrst SBRT case was 
from 2003. Patients who received only palliative treatment 
(as coded in the database) were also excluded from the analy-
sis. For both the surgery and SBRT arms, patients with tumors 
greater than 5 cm in size, clinical T2b disease or clinical N1/2/
unknown or clinical M1/unknown status were excluded. In 
addition, surgical patients who received any neoadjuvant ther-
apy (chemotherapy or radiation) were excluded. Patients who 
were eventually pathologically upstaged or received adjuvant 
therapy after surgery or SBRT were included. The study was 
exempted by the institutional review board.
For each patient, we obtained information on patient-
related variables, tumor-related variables, treatment, and 
short-term (30-day mortality, readmission) and long-term 
(OS) outcomes. Using information on race and income, we 
formed dichotomized groups in which a patient was either 
Caucasian or not Caucasian and had an annual income less 
than or greater than $35,000. In addition, based on the popu-
lation size of the area from which a patient presented rural 
(regional population less than 250,000) and urban locations 
were deﬁned. Comorbidity was annotated using the Charlson/
Deyo score, categorized as 0, 1, or greater than or equal to 
2. The NCDB combined those with scores of 2 or greater 
into one group as very few patients had scores greater than 
2. Treatment facilities are classiﬁed as in the NCDB as com-
munity cancer programs, comprehensive community cancer 
programs, and academic/research centers in the NCDB, and 
the former two were categorized as nonacademic centers for 
the purpose of this analysis.
Last known vital status and the time between diagno-
sis and the last known follow-up date were used to determine 
survival. We initially contrasted patients receiving surgery 
to those who received SBRT in an unmatched comparison. 
Patients in the surgery group were then matched to those in 
the SBRT group using a propensity score based technique. 
The propensity score was the probability of receiving SBRT 
during the study period, estimated using a logistic regres-
sion model including age at diagnosis, gender, race, income, 
rural versus urban status, Charlson/Deyo score, tumor size, 
T1 versus T2 status, and type of facility where treatment was 
administered. These variables were selected from an initial 
univariate analysis comparing the surgery and SBRT groups, 
and variables signiﬁcantly different between the groups were 
chosen for propensity matching. Patients for whom the pro-
pensity scores matched to the fourth decimal place were 
matched in 1:1 fashion. Automated matching was performed 
using the Fuzzy extension command in SPSS (SPSS 21.0 for 
Windows, SPSS Inc., Chicago, IL).15 Recognizing that surgery 
in the form of sublobar resection (wedge resection or segmen-
tectomy) is a closer anatomical approximation to the volume 
of lung parenchyma treated with SBRT and often offered to 
patients at higher risk from lobectomy, we performed a sec-
ondary analysis (unmatched and propensity score matched) 
restricting surgery patients only to those who underwent sub-
lobar resection (Fig. 1).
All statistical analyses were performed using SPSS 
21.0. Descriptive statistics were expressed as mean ± standard 
deviation unless otherwise speciﬁed. Independent samples t 
tests and one-way analysis of variance were used to compare 
continuous variables. Chi-square tests were used to compare 
categorical data. OS was estimated by the Kaplan–Meier 
method. The log-rank test was used to determine differences 
in OS. All statistical tests were two-sided and a 0.05 level of 
signiﬁcance was used.
RESULTS
Between 1998 and 2010, 230,224 patients were diag-
nosed with clinical stage I NSCLC at 1600 institutions. A total 
of 117,618 of 230,224 met study criteria (Fig. 1) and were 
treated with primary surgery (n = 111,731, 95.0%) or SBRT 
(n = 5887, 5.0%). The mean follow-up for the entire study 
group was 36.5 months. The median follow-up was longer for 
surgical patients (27.5 versus 16.6 months, p < 0.001).
Patients in the surgery group were younger and were 
more likely to be males and non-Caucasians (Table 1). 
Surgical patients were also more likely to be from rural areas 
and had higher Charlson comorbidity scores and slightly larger 
tumors. SBRT patients were more likely to have T1 (versus 
T2) tumors and receive treatment at academic centers. In the 
surgery cohort, lobectomy (82,749 of 111,731, 74.1%) was 
the most common operation, whereas the remaining patients 
underwent a sublobar resection (26,292 of 111,731, 23.5%) or 
pneumonectomy (2690 of 111,731, 2.4%). Median postopera-
tive hospital stay was 6 days, and the 30-day surgical mortality 
was 2596 of 109,485 (2.4%). In surgical patients, 1-year OS 
was 90.0%. One-year survival after SBRT was 85.5%.
Postoperatively, 13,610 of 94,086 (14.5%) surgical 
patients with pathologic staging data available were found to 
have pathologic upstaging (ﬁnal pathologic stage II or higher). 
Overall 9.1% of surgical patients received adjuvant chemo-
therapy only, 2.8% received adjuvant radiation alone, whereas 
2.3% received both adjuvant chemotherapy and radiation. In 
the SBRT cohort, the mean radiation dose was 5383 ± 678 Gy, 
and 4.1% of patients received chemotherapy. Median survival 
for unmatched patients receiving surgery versus SBRT was 
68.4 versus 33.3 months, respectively (p < 0.001) (Fig. 2A)
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fIGURE 1. Consort diagram show-
ing schema of study subject selection 
and analysis.
TABLE 1. Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in All Patients with Clinical Stage I 
NSCLC who Received Surgery versus SBRT
Surgery (n = 111,731) SBRT (n = 5887) P Value
Age (yr) 67.9 ± 9.9 74.7 ± 8.7 <0.001
Female gender 59,338 (53.1%) 3208 (54.5%) 0.039
Caucasian 110,560 (90.0%) 5354 (90.9%) 0.019
Urban location 73,644 (65.9%) 3998 (67.9%) 0.002
Income >$35,000/year 71,481 (67.5%) 3806 (68.0%) 0.473
Charlson/Deyo score (available 
total, n = 90,391; surgery, 84,504; 
SBRT, 5887)
0: 42,761 (50.6%) 0: 3489 (59.3%) <0.001
1: 30,401 (36.0%) 1: 1603 (27.2%)
2: 11,342 (13.4%) 2: 795 (13.5%)
Tumor size (mm) 24.1 ± 10.7 23.4 ± 9.5 <0.001
Clinical T stage T1, 80,184 (71.8%) T1, 4477 (76.0%)
T2, 31,547 (28.2%) T2, 1410 (24.0%)
Facility reporting case Nonacademic, 72,174 (64.6%) Nonacademic, 3470 (58.9%) <0.001
Academic, 39,557 (35.4%) Academic, 2417 (41.1%)




Chemotherapy administered 12,514 (11.3%) 241 (4.1%) <0.001
Radiation administered 5694 (5.1%) 5887 (100%) <0.001
Median radiation dose (cGy) 5400 (n=2798) 5400 (n = 5887)
Median survival (mo) 68.4 ± 0.4 33.3 ± 0.8 <0.001
This table shows an unmatched comparison.
NSCLC, non–small-cell lung cancer; SBRT, stereotactic body radiation therapy.
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Propensity score matching between the surgery and SBRT 
groups yielded 5355 matched pairs. These groups were compa-
rable in age, gender, race, location (rural versus urban), income, 
Charlson/Deyo comorbidity, treatment facility type, tumor 
size, and T1 versus T2 status (Table 2). The median postopera-
tive hospital stay was 6 days, and 227 of 5208 (4.4%) patients 
fIGURE 2. A, Kaplan–Meier survival of patients undergoing surgery versus SBRT. This is an unmatched comparison (A) and 
propensity score matched comparison (B). Kaplan–Meier survival of patients undergoing sublobar resection (wedge or segmen-
tectomy) versus SBRT. This is an unmatched comparison (C) and propensity score matched comparison (D).
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experienced unplanned readmissions after surgery. The 30-day 
surgical mortality was 136 of 5355 (2.5%). Median survival 
for matched patients receiving surgery versus SBRT was 62.3 
versus 33.1 months, respectively (p < 0.001) (Fig. 2B). The 
3-year survival for matched patients receiving surgery was 
68.5%, compared with 46.0% for SBRT. Partitioning the 
matched patients into quintiles based on propensity score, the 
median OS for surgical patients from the lowest to the highest 
propensity score was 79.3, 69.5, 62.0, 57.5, and 49.9 months. 
In the matched SBRT group, the corresponding median survival 
was 36.2, 34.8, 30.6, 32.6, and 32.2 months.
In an unmatched comparison of surgical patients under-
going sublobar resection (wedge resection or segmentectomy, 
n = 26,292) with those undergoing SBRT (n = 5887), surgical 
patients were younger, more likely to be treated at nonacademic 
centers, and had higher Charlson comorbidity scores (Table 3). 
Surgical patients also had smaller tumors and were more likely to 
have clinical T1 (versus T2) tumors. Median postoperative hospi-
tal stay was 5 days, and the 30-day surgical mortality was 716 of 
19,339 (3.7%). Overall 6.1% of surgical patients received adju-
vant chemotherapy only, 5.4% received adjuvant radiation alone, 
whereas 2.3% received both adjuvant chemotherapy and radia-
tion. In the SBRT cohort, the mean radiation dose was 5383 ± 678 
Gy, and 4.1% of patients received chemotherapy. Median survival 
for unmatched patients receiving surgery versus SBRT was 51.9 
versus 33.3 months, respectively (p < 0.001) (Fig. 2C).
Propensity score matching between sublobar resection 
only and SBRT groups yielded 4555 matched pairs. These 
groups were comparable in age, gender, race, location (rural 
versus urban), income, comorbidities, treatment facility type, 
tumor size, and T1 versus T2 status (Table 4). The median 
postoperative hospital stay was 5 days, and 176 of 4421 
(4.0%) patients experienced unplanned readmissions after 
surgery. The 30-day surgical mortality was 89 of 4555 (2.0%). 
Median survival for matched patients receiving surgery versus 
SBRT was 48.3 versus 33.9 months, respectively (p < 0.001) 
(Fig. 2D). The 3-year survival for matched patients receiv-
ing sublobar resection was 61.7%, compared with 47.0% for 
SBRT. Partitioning the matched patients into quintiles based 
on propensity score, the median OS for sublobar resection sur-
gery patients from the lowest to the highest propensity score 
was 69.5, 51.2, 47.3, 43.9, and 39.3 months. In the matched 
SBRT group, the corresponding median survival was 40.9, 
39.7, 32.9, 32.2, and 28.9 months. A separate subgroup anal-
ysis of patients with Charlson score 2 was also performed 
(Supplemental Table, Supplemental Digital Content, http://
links.lww.com/JTO/A892).
With the understanding that patients recorded in the 
most recent time period included in the NCDB may have 
less complete follow-up that those from the prior period, we 
undertook several subset analyses to conﬁrm the validity of 
our ﬁndings in the overall cohort. We propensity matched 
patients undergoing surgery to those undergoing SBRT in 
the time period before 2007. In addition, we performed a 
separate propensity matched analysis where the year of 
diagnosis was also included as a matching variable to com-
pare patients undergoing surgery or SBRT. Finally, we per-
formed these two analyses (pre 2007 era, and matching by 
TABLE 2. Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in Propensity Score Matched 
Patients with Clinical Stage I NSCLC who Received Surgery versus SBRT
Surgery (n = 5355) SBRT (n = 5355) P Value
Age (yr) 74.2 ± 8.4 74.3 ± 8.5 0.522
Female gender 2973 (55.5%) 2948 (55.1%) 0.627
Caucasian 4838 (90.3%) 4864 (90.8%) 0.390
Urban location 3806 (71.1%) 3785 (70.7%) 0.671
Income >$35,000/yr 3661 (68.4%) 3661 (68.4%) 1
Charlson/Deyo score 0 3160 (59.0%) 0: 3102 (57.9%) 0.406
1: 1446 (27.0%) 1: 1507 (28.1%)
2: 749 (14.0%) 2: 746 (13.9%)
Tumor size (mm) 23.3 ± 10.3 23.4 ± 9.5 0.739
Clinical T stage T1, 4099 (71.8%) T1, 4063 (75.9%) 0.414
T2, 1256 (28.2%) T2, 1292 (24.1%)
Facility reporting case Nonacademic, 3146 (58.7%) Nonacademic, 3183 (59.4%) 0.479
Academic, 2209 (41.3%) Academic, 2172 (40.6%)




Chemotherapy administered 486 (9.2%) 226 (4.3%) <0.001
Radiation administered 198 (3.7%) 5355 (100%) <0.001
Median radiation dose (cGy) 5600 (n = 141) 5400 (n = 5355)
Median survival (mo) 62.3 ± 1.7 33.1 ± 0.8 <0.001
NSCLC, non–small-cell lung cancer; SBRT, stereotactic body radiation therapy.
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year of diagnosis) comparing patients undergoing SBRT 
or sublobar resection. In all of these subset analyses, our 
ﬁndings from the overall cohort of patients were similar in 
direction and magnitude.
DISCUSSION
These data suggest that patients with clinical stage 
I NSCLC selected to undergo surgery have longer OS than 
those who undergo SBRT in both unmatched and propensity 
TABLE 4. Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in Propensity Score Matched 
Patients with Clinical Stage I NSCLC who Received Sublobar Resection (Wedge Resection or Segmentectomy) versus SBRT
Surgery (n = 4555) SBRT (n = 4555) P Value
Age (yr) 73.7 ± 8.2 73.8 ± 8.5 0.751
Female gender 2504 (55.0%) 2556 (56.1%) 0.282
Caucasian 4166 (91.5%) 4164 (91.4%) 0.940
Urban location 3214 (70.6%) 3193 (70.1%) 0.646
Income >$35,000/yr 3119 (68.5%) 3139 (68.9%) 0.651
Charlson/Deyo score 0: 2525 (55.4%) 0: 2459 (54.0%) 0.366
1: 1378 (30.3%) 1: 1414 (31.0%)
2: 652 (14.3%) 2: 682 (15.0%)
Tumor size (mm) 21.8 ± 9.4 21.9 ± 8.6 0.481
Clinical T stage T1, 3641 (79.9%) T1, 3647 (80.1%) 0.896
T2, 914 (20.1%) T2, 908 (19.9%)
Facility reporting case Nonacademic, 2674 (58.7%) Nonacademic, 2726 (59.8%) 0.268
Academic, 1881 (41.3%) Academic, 1829 (40.2%)
Type of operation Wedge, 3745 (82.2%)
Segment, 810 (17.8%)
Chemotherapy administered 394 (8.7%) 187 (4.2%) <0.001
Radiation administered 360 (7.9%) 4555 (100%) <0.001
Median radiation dose (cGy) 5940 (n = 256) 5400 (n = 4555)
Median survival (mo) 48.3 ± 1.2 33.9 ± 0.9 <0.001
NSCLC, non–small-cell lung cancer; SBRT, stereotactic body radiation therapy.
TABLE 3. Baseline Characteristics, Treatment-Related Variables, and Long-Term Outcomes in All Patients with Clinical Stage I 
NSCLC who Received Sublobar Resection (Wedge Resection or Segmentectomy) versus SBRT
Surgery (n = 26,292) SBRT (n = 5887) P Value
Age (yr) 70.1 ± 9.3 74.7 ± 8.7 <0.001
Female gender 14,670 (55.8%) 3208 (54.5%) 0.070
Caucasian 24,016 (91.3%) 5354 (90.9%) 0.332
Urban location 17,710 (67.4%) 3998 (67.9%) 0.415
Income >$35,000/yr 17,172 (68.8%) 3806 (68.0%) 0.202
Charlson/Deyo score (available total  
n = 25,846; surgery, 19,959; SBRT, 5887)
0: 9087 (45.5%) 0: 3489 (59.3%) <0.001
1: 7662 (38.4%) 1: 1603 (27.2%)
2: 3211 (16.1%) 2: 795 (13.5%)
Tumor size (mm) 19.3 ± 9.0 23.4 ± 9.5 <0.001
Clinical T stage T1, 80,184 (71.8%) T1, 4477 (76.0%) <0.001
T2, 31,547 (28.2%) T2, 1410 (24.0%)
Facility reporting case Nonacademic, 16,353 (62.2%) Nonacademic, 3470 (58.9%) <0.001
Academic, 9939 (37.8%) Academic, 2417 (41.1%)
Type of operation Wedge, 22,010 (83.7%)
Segment, 4282 (16.3%)
Chemotherapy administered 2193 (8.4%) 241 (4.1%) <0.001
Radiation administered 2015 (7.7%) 5887 (100%) <0.001
Median radiation dose (cGy) 5750 (n = 1033) 5400 (n = 5887)
Median survival (mo) 51.9 ± 0.5 33.3 ± 0.8 <0.001
This table shows an unmatched comparison.
NSCLC, non–small-cell lung cancer; SBRT, stereotactic body radiation therapy.
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score matched comparisons. In subgroup analyses of sublobar 
lung resection versus SBRT, the difference persists albeit at 
a smaller magnitude. Lobectomy with mediastinal lymph 
node sampling/dissection is considered the standard of care 
for low-risk patients with early-stage NSCLC. More limited 
lung resection (wedge/segmentectomy) has been reserved for 
patients with suboptimal lung function or other signiﬁcant 
comorbidities or very small/ground-glass nodules. SBRT was 
initially introduced as an alternative to conventionally frac-
tionated radiation therapy for medically inoperable patients 
with early-stage NSCLC. SBRT has become the preferred 
treatment in the medically inoperable population based on 
high rates of local control, convenience, and suggestion of 
better survival compared with historic outcomes after conven-
tional radiation.16,17 The application of SBRT has expanded to 
patients who are medically operable2,5 but may be at an ele-
vated risk for perioperative adverse outcomes and these deci-
sions for treatment allocation in high-risk patients are often 
made subjectively on an individual basis due to lack of evi-
dence based guidelines.
A number of retrospective institutional studies have 
compared surgery and SBRT for clinical stage I NSCLC using 
propensity score matched analyses1–4,9 or multivariate regres-
sion models.7 Although most authors, including those of a 
recent meta-analysis, have noted a longer OS in the surgical 
patients,3,7–10 others have found equivalent intermediate-term 
OS.2,4 Evaluating cancer-speciﬁc outcomes, some studies have 
reported a longer DFS with surgery,9 whereas others have found 
no differences between the treatment arms.3 In addition, previ-
ous publications have noted similar cancer-speciﬁc survival 
(CSS) after surgery or SBRT.8,10 Several retrospective studies 
comparing locoregional tumor control between surgery and 
SBRT have been criticized for having inconsistent deﬁnitions 
for locoregional failure between the two arms. Two recent 
analyses using uniform deﬁnitions of locoregional failure 
have reported better local control rates with surgery; however, 
regional and distant control rates seem to be similar.8,9 Most 
of the above-mentioned studies have included lobectomy and 
sublobar resection patients in the surgical cohorts. Only two 
direct comparisons of wedge resection and SBRT have been 
reported with one study showing no differences in recurrence 
patterns for the two arms and longer OS with surgery,7 and the 
other demonstrating superior disease control with surgery but 
equivalent OS.6 A recent propensity matched analysis based 
on institutional data revealed similar cause-speciﬁc survival in 
patients treated with sublobar resection or SBRT.18 The same 
group published a propensity matched analysis of patients 
treated with video-assisted thoracoscopic surgery lobectomy 
and SBRT and noted better OS and cause-speciﬁc survival in 
the video-assisted thoracoscopic surgery lobectomy group.19 
A potential problem in any retrospective comparison of treat-
ment modalities is the difference in radiographic follow-up 
that typically deﬁnes locoregional recurrences. Computed 
tomography or positron emission tomography scans are often 
employed every 3 months for patients treated with SBRT and 
typically at 6-month intervals for surgical patients.
Two recent comparative studies have utilized the 
Surveillance, Epidemiology, and End Results database linked 
to Medicare to compare surgery and SBRT. Shirvani et al.11 
studied elderly patients with NSCLC treated between 2003 
and 2009 in multivariate and propensity matched analyses and 
concluded that lobectomy was associated with better outcomes 
than sublobar resection, and propensity score matching sug-
gested that SBRT may be a good option among patients with 
very advanced age and multiple comorbidities. Yu et al.12 stud-
ied patients treated between 2007 and 2009 and noted that for 
patients with short life expectancies (<5 years), there was no 
difference in lung cancer mortality between surgery and SBRT. 
However, for patients with long life expectancies, there was 
greater overall mortality and a trend toward greater lung cancer 
mortality with SBRT versus surgery.12 Our study adds to the 
information from these analyses by involving a larger national 
data set, including all age groups of patients, and not only the 
elderly lung cancer population, and by conducting distinct anal-
yses for various subgroups including those undergoing sublobar 
resection and patients with higher comorbidity scores.
We noted longer survival in surgical patients in this 
national sample; however, the database does not include 
information about DFS or CSS. In addition, data concerning 
locoregional or distant recurrences are unavailable. On the 
basics of the aforementioned studies, any anticipated advan-
tage of surgery regarding recurrence patterns would likely be 
moderate, and therefore, unlikely to completely account for 
the large differences in OS observed in our study (median 
survival 62 versus 33 months). Similarly, the more frequent 
administration of chemotherapy in the surgical cohort (9.2% 
versus 4.3%) and the relative survival beneﬁt of this adjuvant 
therapy cannot explain the difference in OS.20 This observa-
tion suggests an inherent selection bias whereby healthier 
patients are more likely to have been allocated to the surgical 
arm despite our efforts to match these patients. We suspect 
that still there must be unmeasured covariates that influence 
treatment allocation for which this propensity score matching 
process cannot completely account.
In studying the sublobar resection propensity score 
matched patients by quintiles of propensity score (with higher 
propensity scores likely reflecting increased perceived surgical 
risk), we noted that median OS for the highest risk quintile sub-
lobar resection group patients was 39 months and approached 
the survival of that of the overall matched SBRT cohort includ-
ing all matched patients (34 months). These ﬁndings indicate 
that the highest propensity score quintile includes the greatest 
risk surgical patients and comprises those where a multidisci-
plinary team may have equipoise about the treatment modality 
especially if sublobar resection is being considered. The char-
acterization of this high-risk group of patients, however, is not 
possible with the information available in the current database.
Previous studies, including national cooperative group 
trials, have utilized arbitrary parameters based on expert 
opinion to classify possible surgical patients as high risk.21,22 
These high-risk parameters for auditing a clinical trial has 
been shown to be misleading if used to guide clinical care.23 
A number of risk stratiﬁcation models have been developed 
for patients undergoing lung resection using large national 
and international databases for model development and 
validation.24–29 Among these models, the European Society 
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Objective Score,24 the Thoracoscore,27 and a model derived 
from the Society of Thoracic Surgeons database25 are the 
most prominent. The Thoracoscore was developed from a 
large French database and is composed of nine variables pre-
dicting hospital mortality.27 Kozower et al.25 have described 
a regression model that associated more than 15 variables 
with a composite outcome of major morbidity or mortality. 
Unfortunately, these models have found very limited applica-
tion in daily clinical surgical practice, whereas no such mod-
els have been proposed for the SBRT population. It is likely 
that the previously utilized risk models based on surgical 
patients alone are inadequate at guiding treatment allocation 
(i.e., operative versus nonoperative therapy) because they fail 
to capture the spectrum of patients that are turned down for 
surgery. This subjectivity in treatment allocation is reflected 
even in the current analysis where there is a greater propor-
tion of patients with Charlson score 1 in the surgical cohort, 
though the distribution of those with Charlson score 2 is simi-
lar between the surgical and SBRT patients. It is, therefore, 
imperative to have clinically applicable, validated risk models 
built with data from medically inoperable and high-risk surgi-
cal patients so that those designated in each category can be 
offered the appropriate treatment or counseled on the relative 
risk and beneﬁts of each therapy when outcomes are deemed 
to be equivalent.
It is apparent, based on the limitations of the existing 
literature, that rigorous, prospective studies can better show 
the relative efﬁcacy of surgery and SBRT in high-risk patients 
while simultaneously providing us with objective deﬁnitions 
of inoperable and high-risk patients. Unfortunately three tri-
als attempting to answer these questions have failed to accrue 
and have been closed. These included the Radiosurgery Or 
Surgery for operable Early-stage non–small-cell Lung can-
cer (ROSEL) trial in Holland, Randomized Study to Compare 
CyberKnife Stereotactic Radiotherapy With Surgical 
Resection in Stage I Non–small-Cell Lung Cancer (STARS) 
trial, and the American College of Surgeons Oncology Group 
Z4099/Radiation Therapy Oncology Group 1021. In light of 
these failures, a reasonable, stepwise alternative approach 
may be to create a multi-institutional registry of all patients 
with clinical stage I NSCLC being evaluated for SBRT or 
surgery.
Our study has some strengths and limitations when 
compared with prior publications. It includes information 
from a national database that reflects actual practice patterns 
for all environments where patients with early-stage NSCLC 
receive care. Thus, the ﬁndings are more likely to generalize 
to the population when compared with reports from highly 
specialized treatment centers. The large sample size available 
for primary and secondary analyses is another advantage com-
pared with institutional studies where subset analysis may be 
underpowered. However, despite propensity score matching, 
our retrospective analysis likely misses a signiﬁcant selec-
tion bias in treatment allocation, such that lower risk patients 
may have been preferentially allocated to surgery. The accu-
racy of individual observations in large databases is arguably 
lower than that in closely monitored clinical trials; however, 
the general trend of short-term and long-term outcomes we 
observed is similar to prior cohort studies. In addition, DFS 
and CSS, important parameters in long-term follow-up of a 
cohort of cancer patients, are unavailable from the NCDB.
We conclude that patients with clinical stage I NSCLC 
selected for surgery seem to show better long-term OS com-
pared with those underwent SBRT. Outcomes in both treat-
ment cohorts are strongly influenced by comorbidity and risk. 
Unmeasured covariates likely play an important part in treat-
ment allocation and may be associated with survival. Rigorous 
prospective studies are urgently needed to accurately deﬁne 
the high-risk surgical patient and optimize patient selection 
for SBRT in this population.
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